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27 Abstract 
 
28 Despite our increasing understanding of the pathophysiology underlying chronic or 
 
29 maladaptive pain, there is a significant gap in our ability to diagnose and treat the condition in 
 
30 domestic cats. Newer techniques being used to identify abnormalities in pain processing in the 
 
31 cat include validated owner questionnaires, measurement of movement and activity, and 
 
32 measurement of sensory thresholds and somatomotor responses. While some data are available 
 
33 evaluating possible therapeutics for the treatment of chronic pain in the cat, most data are limited 
 
34 to normal cats. This review details our current understanding of chronic or maladaptive pain, 
 
35 techniques for the detection and measurement of the condition and the associated central nervous 
 
36 changes, as well as an overview of the data evaluating potential therapeutics in cats. 
 
37 
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39 Introduction 
 
40 While cats have become a very popular pet worldwide- with an estimated 75+ million in 
 
41 the US alone, the assessment and treatment of pain in cats has lagged behind that of dogs 
 
42 (Robertson, 2008b). Though this knowledge gap is diminishing, most information on pain 
 
43 control in cats exists regarding peri-operative analgesic use, (Brondani et al., 2011; Johnson, 
 
44 2013; Calvo et al., 2014; Epstein et al., 2015) with chronic pain conditions still being 
 
45 undiagnosed and under-treated (Robertson, 2008b; Lascelles and Robertson, 2010; Lorena et al., 
 
46 2013). Chronic pain situations typically don’t have easily identifiable inciting incidents and the 
 
47 behavioral changes develop slowly and are often subtle. This makes measurement of chronic or 
 
48 long-standing pain conditions difficult, and although recent progress has been made in the 
 
49 development of tools to assess chronic pain (Zamprogno et al., 2010; Benito et al., 2012; Benito 
 
50 et al., 2013; Gruen et al., 2015) our ability to measure chronic pain lags behind that of acute pain 
 
51 in veterinary species. The relative lack of validated methods of chronic pain assessment 
 
52 contributes to our inability to assess efficacy of analgesics for the alleviation of such pain in cats. 
 
53 This review details our current understanding of chronic or maladaptive pain, techniques for the 
 
54 detection and measurement of the condition and the associated central nervous changes, as well 
 
55 as an overview of the data evaluating potential therapeutics in the cat. 
 
56 
 
57 The literature review was performed by searching on several databases, including 
 
58 PubMed, CAB Abstracts, and Google Scholar. Specific search for medications of interest were 
 
59 based on: personal experience, use, or knowledge, anecdotal reports of use or efficacy, 
 
60 recommendations and guidelines for the treatment of pain in cats, medications being currently 
61 researched, etc. Keywords used included: pain, chronic pain, maladaptive pain, feline, feline 
 
62 pain, osteoarthritis, degenerative joint disease, analgesics, pharmacokinetics, efficacy, etc. 
 
63 
 
64 Chronic maladaptive pain 
 
65 Chronic pain has been defined in human medicine as any pain that lasts more than 3-6 
 
66 months (Merskey and Bogduk, 1986), but the relevance of this timeline to veterinary species 
 
67 with considerably shorter lifespans should also be considered. Different disease conditions like 
 
68 cancer may also affect the timeline, as it may not be prudent to ‘delay’ treatment, or pathologies 
 
69 where the normal healing and recovery period is expected to be much shorter. This difficulty in 
 
70 clearly demarcating the transition from acute to chronic pain has led to a growing realization that 
 
71 previously termed acute and chronic pain are actually on a continuum, and alternative definitions 
 
72 may be more useful in the context of understanding pain and how to treat it (Woolf, 2010). 
 
73 Recently, the terms ‘adaptive’ and ‘maladaptive’ have been suggested as terms that better 
 
74 describe pain (Figs. 1 and 2). Adaptive pain encompasses both nociceptive and inflammatory 
 
75 pain (Woolf, 2010). Nociceptive pain is only activated by high-threshold noxious stimuli, 
 
76 including stimuli that cause tissue injury. Inflammatory pain occurs after tissue damage and 
 
77 produces heightened sensitivity of the tissue associated with a classical inflammatory response. 
 
78 Both of these types of pain are considered protective, or ‘adaptive’ pain in that they serve to 
 
79 sense and/or avoid actual or potential tissue damage. These typically have an easily identifiable 
 
80 cause (surgery, injury, etc.), and are reversible. Maladaptive pain, on the other hand, is not 
 
81 protective, and is primarily due to plastic changes in the pain processing system. It can be further 
 
82 divided into neuropathic pain, which is pain resulting from direct damage to neural tissue, and 
 
83 functional pain, where there are no neural lesions or inflammation, and pain is driven by 
84 dysfunction or malfunction of the nociceptive system. Classically, neuropathic pain is thought of 
 
85 as resulting from gross, obvious damage to the spinal cord, or obvious damage to peripheral 
 
86 nerves such as with peripheral nerve sheath tumors or surgical trauma. However, increasingly it 
 
87 is recognized that many diseases, such as osteoarthritis (OA) and cancers, may involve a degree 
 
88 of peripheral neuropathy via either direct damage to nerve endings present in the tissues, or via 
 
89 increased innervation that accompanies joint remodeling and angiogenesis (Ivanavicius et al., 
 
90 2007; Im et al., 2010; Bennett et al., 2012; French et al., 2017). This explains the neuropathic 
 
91 pain-like symptoms reported in many human patients with OA. Similarly, the obvious example 
 
92 of functional pain is phantom limb pain or fibromyalgia– there is no evidence of a peripheral 
 
93 lesion or inflammation, yet there is increased sensitivity to stimuli and spontaneous pain. Yet 
 
94 increasingly, it is recognized that many conditions, such as OA, have a component of functional 
 
95 pain – changes in the central nervous system function that heightens sensitivity or results in 
 
96 spontaneous pain. It has been previously suggested that there is a central or maladaptive drive to 
 
97 pain in a significant portion (20-40%) of human patients suffering from osteoarthritis-associated 
 
98 pain (Crawford et al., 1998; Ivanavicius et al., 2007). This underscores the importance of 
 
99 understanding the driving factors of a patient’s pain, as one patient may suffer from multiple 
 
100 types. 
 
101 
 
102 Central to the concept of maladaptive pain is the phenomenon of central plasticity (also 
 
103 referred to as central sensitization), initiated through cellular wind up (Woolf, 2011). While 
 
104 wind-up is a neuron’s increasing response/output resulting from repeated, identical stimuli, 
 
105 central plasticity is the global response that lasts autonomously after the conditioning (original) 
 
106 stimulus has been discontinued, or is sustained with low level nociceptor input from the 
107 periphery (Woolf, 2011). This results in a stronger painful reaction to a less intense 
 
108 (hyperalgesia) or previously innocuous stimulus (allodynia), and increases in the receptive fields 
 
109 of neurons, or the region of tissue that a neuron functionally innervates and responds to stimuli 
 
110 in. Central plasticity is driven by changes at various levels of the sensory transmission axis – 
 
111 primary afferent fiber, spinal cord and higher centers. In general, the processes driving central 
 
112 plasticity are a combination of increased neuronal excitability, facilitated synaptic transmission 
 
113 and decreased inhibitory influences (Woolf, 2011). However, as well as a gain in function, some 
 
114 processes are down-regulated (loss of gain) and so the term central plasticity is preferred over 
 
115 central sensitization. 
 
116 
 
117 Clinical long-standing pain (chronic pain) is a complex mixture of adaptive 
 
118 (inflammatory) and maladaptive (neuropathic, functional) pain. It is likely that different 
 
119 neurobiological processes are responsible for the different components of long-standing pain, but 
 
120 it is also likely that there is tremendous overlap. Most information about the processes involved 
 
121 in the maladaptive component of long-standing pain have been derived from work in rodents, 
 
122 using models of neuropathic pain. A multitude of mechanisms play varying roles in maladaptive 
 
123 pain states, and a laudable clinical goal would be to be able to understand the mechanisms 
 
124 responsible for pain in an individual, and so make informed choices about analgesics. Currently 
 
125 it is impossible to predict the mechanisms responsible for the pain state in individual patients, 
 
126 however, progress is being made in this area, with recent studies in humans testing the function 
 
127 of the endogenous analgesic mechanisms to predict response to analgesics (Yarnitsky 2012; 
 
128 Edwards 2016). 
 
129 
130 Most chronic diseases that are associated with pain consist of several different pain 
 
131 components, including both an active, sustained inflammatory component (as in degenerative 
 
132 joint disease, gingivostomatitis, and others) as well as the maladaptive pain with associated 
 
133 neuronal changes and sensitization (Lee et al., 2011; Woolf, 2011; Baron et al., 2013). Although 
 
134 is it not easy to clinically recognize inflammatory versus maladaptive pain states, there is 
 
135 increasing recognition that many common long-standing diseases are associated with central 
 
136 plasticity, and so maladaptive pain. Indeed, it was recently shown that dogs with OA have 
 
137 measureable central sensitization indicative of maladaptive pain (Knazovicky et al., 2016). 
 
138 Commonly occurring diseases that are possibly associated with a component of maladaptive pain 
 
139 in the cat include osteoarthritis and degenerative joint disease, interstitial cystitis, 
 
140 gingivostomatitis, diabetic neuropathy, cancers, ocular pathology (including glaucoma, chronic 
 
141 anterior uveitis),  dermatological conditions (including chronic infections, burns, slow-healing 
 
142 wounds, secondary effects of radiation therapy), and others (Robertson and Lascelles, 2010). 
 
143 
 
144 It is important to clarify that chronic pain can exist on a continuum, and can in fact be 
 
145 comprised of multiple driving mechanisms. In some chronically painful conditions, the driving 
 
146 condition may start and remain as inflammatory pain, with an easily understood coupling of 
 
147 peripheral disease with degree of pain. In these painful conditions, nonsteroidal anti- 
 
148 inflammatory drugs (NSAIDs) are expected to be effective. However, it is likely that in many 
 
149 cases, the ongoing nociceptive input into the nervous system, along with damage to nerve 
 
150 endings as a result of the peripheral disease process can cause changes in the central nervous 
 
151 system and therefore produce maladaptive pain. It is this maladaptive component that makes 
 
152 chronic pain difficult to treat. Hence the search for novel, non-NSAID therapies that can be used 
153 along with, or in place of, NSAIDs. At this moment, we are limited in that we cannot clinically 
 
154 differentiate between maladaptive pain, and pain with a purely inflammatory drive. 
 
155 
 
156 Assessment of chronic pain in cats 
 
157 Recently, progress has been made in the assessment of chronic pain in the cat using 
 
158 owner questionnaires, called Clinical Metrology Instruments (CMIs). The two most studied 
 
159 CMIs are the Client Specific Outcome Measures (CSOM) and Feline Musculoskeletal Pain Index 
 
160 (FMPI; Gingerich and Strobel, 2003; Lascelles et al., 2007; Lascelles et al., 2008; Lascelles et 
 
161 al., 2010; Benito et al., 2013; Gruen et al., 2015). 
 
162 
 
163 The objective measurement of movement or activity also have been developed as 
 
164 methods to assess the impact of chronic/maladaptive pain and its treatment. Recently, activity 
 
165 monitors that record changes in acceleration associated with movement have been used as an 
 
166 objective outcome measure of mobility in cats (Lascelles et al., 2010; Guillot et al., 2012; Gruen 
 
167 et al., 2014). Cats are fitted with a small accelerometer on a collar or harness, and allowed to 
 
168 move about normally in their home environment. This the tool can discriminate between normal 
 
169 and affected research cats (Guillot et al., 2012), and can even be used to show treatment effects 
 
170 in client-owned affected cats (Lascelles et al., 2007; Lascelles et al., 2010; Guillot et al., 2013; 
 
171 Gruen et al., 2014; Gruen et al., 2016). 
 
172 
 
173 To understand the mal-function of the somatosensory system present with maladaptive 
 
174 pain, methods evaluating sensorimotor function are needed. Quantitative sensory testing (QST) 
 
175 involves the measurement of the stimulus (mechanical, thermal hot/cold, etc.) strength or 
176 frequency of application required to elicit a withdrawal or response (e.g. head turn, limb 
 
177 withdrawal) by the patient, with the end of the test usually determined by observation of the 
 
178 response. It is useful for semi-objectively assessing changes in sensation, especially in relation to 
 
179 central plasticity, and its associated allodynia, hyperalgesia, enhanced temporal summation (an 
 
180 increasing response to repetitive stimuli), etc. (Guillot et al., 2014). While QST is in its early 
 
181 development in cats, it can discriminate between healthy, non-affected cats, and those with OA 
 
182 (Guillot et al., 2014). Other methods such as the measurement of Nociceptive Withdrawal 
 
183 Reflexes (NWR) have been explored in dogs, but not yet in cats (Bergadano et al., 2006; Hunt et 
 
184 al., 2016). NWR Testing measures the magnitude of the withdrawal responses to various stimuli 
 
185 using EMG. This modality can evaluate the threshold to elicit withdrawal, in addition to the 
 
186 effect on withdrawal latency and magnitude after delivering repeated stimuli (temporal 
 
187 summation). Data produced are objective, as opposed to the semi-objective QST methodology. 
 
188 NWR testing is proposed to measure central plasticity and associated changes in pain processing, 
 
189 and affected patients are expected to have lower thresholds and higher or stronger EMG 
 
190 responses. 
 
191 
 
192 Overall, our ability to accurately measure chronic pain is limited, and our ability to 
 
193 measure the maladaptive component of this pain is even more restricted. As a result, diagnosis 
 
194 and treatment of the disorder often involves ‘trial and error’ on the part of the clinician. 
 
195 
 
196 Treatment of maladaptive pain in cats 
 
197 In North America, there are no drugs approved for long-term use in cats with maladaptive 
 
198 pain, and only one NSAID (meloxicam) is approved for long-term use in some parts of the 
199 world. Despite recent information suggesting that NSAID therapy can partly reverse central 
 
200 plasticity (Arendt-Nielsen et al., 2016), it is generally accepted that the maladaptive component 
 
201 of pain conditions is poorly responsive to NSAIDs (Edwards et al., 2016). Because there are also 
 
202 concerns around the potential for adverse effects from NSAIDs, interest in alternative drug 
 
203 therapy has emerged. Currently, drug choices are based on experience in people, or because of 
 
204 their activity on mechanisms shown to be important in rodent models of maladaptive pain. 
 
205 Medications that have been suggested for use in cats for the treatment of maladaptive pain are 
 
206 gabapentin, tramadol, amantadine, amitriptyline, tapentadol, flupirtine and anti-nerve growth 
 
207 factor antibodies (Table 1). This review outlines what is currently known about non-NSAID drug 
 
208 treatments that may be effective for chronic or maladaptive pain in cats. 
 
209 
 
210 Gabapentin 
 
211 Gabapentin is an analogue of the neurotransmitter γ-Aminobutyric acid (Kukkar et al., 
 
212 2013; Patel and Dickenson, 2016). Gabapentin exerts its effects on voltage-gated calcium 
 
213 channels, which are found on excitatory cells such as neurons. These channels respond to 
 
214 depolarization currents by allowing the influx of calcium ions (Dolphin, 2016). Four subunits of 
 
215 calcium channels have been identified, the main pore-forming α1 subunit, and the accessory α2δ, 
 
216 β, and γ subunits (Dolphin, 2016). Models of neuropathic pain have demonstrated an increase in 
 
217 the α2δ-1 subunit in dorsal root ganglion (DRG) and dorsal horn neurons (Luo et al., 2001; Bauer 
 
218 et al., 2009). This subunit and binding target for gabapentin is responsible for guiding or 
 
219 trafficking of α1 subunits and therefore pore assembly, indicating a vital role of the α2δ-1 subunit 
 
220 in altered neuronal excitability and pain processing (Luo et al., 2001; Bauer et al., 2009; Dolphin, 
 
221 2016; Patel and Dickenson, 2016). This binding results in a decrease in the influx of calcium ions 
222 in response to an action potential, and therefore decreased neurotransmitter release or neuronal 
 
223 excitability. Gabapentin has been advocated for the treatment of neuropathic pain in veterinary 
 
224 species because of experience treating neuropathic pain in humans (Backonja et al., 1998; 
 
225 Kukkar et al., 2013; Moore et al., 2014; Larsen et al., 2016). In people it is only approved for 
 
226 postherpetic neuralgia, and as an adjunctive therapy for partial onset seizures, which are 
 
227 undocumented syndromes in animals. 
 
228 
 
229 The pharmacokinetics of oral (10 mg/kg) and intravenous (4 mg/kg) gabapentin in 6 adult 
 
230 spayed female cats has been described (Siao et al., 2010). While bioavailability varied greatly 
 
231 (range: 49.6 – 118.3%), potentially partially due to ad libitum feeding, the half-life after oral 
 
232 administration was approximately 3 h (177  25 min), with peak concentrations (Cmax) values 
 
233 ranging from 4.6–10.6 µg/mL (Siao et al., 2010). Previously reported data and modeling 
 
234 suggests a half maximal effective concentration (EC50) ranging from 1.4 and 16.7 µg/mL for 
 
235 treatment of hyperalgesia in the rat (Taneja et al., 2012; Taneja et al., 2013; Larsen et al., 2016) 
 
236 and an EC50 of 5.4 µg/mL was estimated for humans with neuropathic pain (Lockwood et al., 
 
237 2003). The authors then suggested a dosing regimen of 8 mg/kg every 6 h for an antihyperalgesia 
 
238 effect in the cat (Siao et al., 2010). However, caution is urged when extrapolating effective 
 
239 concentrations of the drug in cats based on pharmacokinetic-pharmacodynamic data from other 
 
240 species. There is also a current lack of information on pharmacokinetics after repeated dosing. 
 
241 Minimal or no plasma protein binding has been reported in other species, however this should be 
 
242 confirmed in the cat (Radulovic et al., 1995). 
 
243 
244 Currently, there are no clinical studies evaluating the efficacy of gabapentin in chronic 
 
245 pain conditions in cats. In a study evaluating the effects of gabapentin on nociceptive thermal 
 
246 thresholds in research cats (Pypendop et al., 2010), six female spayed adult cats received four 
 
247 dosages of oral gabapentin: 0 (placebo), 5, 10, and 30 mg/kg in a crossover design. Peak plasma 
 
248 concentrations ranged from 6.3 ± 1.3 µg/mL for the 5 mg/kg dosage, to 25.5 ± 8.6 µg/mL after 
 
249 administration of 30 mg/kg. Despite these plasma concentrations, there was no significant effect 
 
250 on thermal thresholds. This is not unexpected as the mechanism of action gabapentin suggests it 
 
251 would only show efficacy when α2δ-1 subunits are expressed in an abnormal, hyperalgesic state. 
 
252 
 
253 Several case studies describing the use of gabapentin exist (Vettorato and Corletto, 2011; 
 
254 Lorenz et al., 2012). One report details chronic use of gabapentin in three cats, following road 
 
255 trauma (n=2) or for musculoskeletal pain (n=1; Lorenz et al., 2012). Another case report details 
 
256 chronic gabapentin use after traumatic incidents (Vettorato and Corletto, 2011). In these case 
 
257 reports there was no objective or validated assessment of response. These individual 
 
258 uncontrolled case reports may not be helpful because of the high placebo effects in owner reports 
 
259 (Gruen et al., 2014; Gruen et al., 2017). Additional research evaluating safety and efficacy 
 
260 treating chronic or maladaptive pain is necessary before treatment recommendations should be 
 
261 made. 
 
262 
 
263 Tramadol 
 
264 Tramadol is an opioid-like drug that exerts its effects via many different mechanisms of 
 
265 action including very weak µ-opioid effects, norepinephrine and serotonin reuptake inhibition, 
 
266 and binding of α2 adrenergic receptors in the pain pathway (Raffa et al., 1992; Faron-Górecka et 
267 al., 2004). The drug is formulated with mixed enantiomers, each with slightly different effects. 
 
268 The first metabolite, M1 (o-desmethyltramadol), may be responsible for the majority of the 
 
269 analgesic effect in humans through opioidergic actions (Duhmke et al., 2004; Norrbrink and 
 
270 Lundeberg, 2009). 
 
271 
 
272 The pharmacokinetics of oral (5mg/kg) and intravenous (2mg/kg) tramadol in cats has 
 
273 been described (Pypendop and Ilkiw, 2007; Cagnardi et al., 2011). Oral bioavailability was 
 
274 reported as high, at 93% ± 7, with a terminal half-life of 4.82  0.32hr for M1 (Pypendop and 
 
275 Ilkiw, 2007). The mean M1 CMAX values after IV dosing were 0.37 and 0.81µg/mL (Pypendop 
 
276 and Ilkiw, 2007; Cagnardi et al., 2011). Both studies found a ratio of tramadol: M1 of  1, which 
 
277 contrasts with dogs which do not appear to produce the M1 metabolite (Giorgi et al., 2009). 
 
278 While more data needs to be collected about minimum effective concentration, the 
 
279 pharmacokinetic data collected so far is promising. 
 
280 
 
281 There have been two studies evaluating the efficacy of tramadol either alone, or in 
 
282 combination with meloxicam, in research cats with naturally occurring chronic OA-associated 
 
283 pain (Monteiro et al., 2016; Monteiro et al., 2017). In the first study, tramadol (3 mg/kg orally 
 
284 every 12 h) was compared against placebo in 15 meloxicam-treated cats (oral transmucosal 
 
285 preparation, 0.05 mg/kg every 24 h) with radiographically confirmed OA (Monteiro et al., 2016). 
 
286 Peak vertical force (PVF, expressed as % bodyweight), accelerometer-based motor activity 
 
287 (MA), and response to mechanical temporal summation (RMTS- determined by the number of 
 
288 subthreshold stimuli required for response) were measured at baseline, and after 21-25 days of 
 
289 treatment. The group found that while both cohorts showed improvement in PVF, cats receiving 
290 only meloxicam showed improvement in motor activity, and only cats receiving both meloxicam 
 
291 and tramadol showed improvement (increase) in RMTS. 
 
292 
 
293 In the second study, 15 cats with radiographically confirmed OA, and five cats without 
 
294 OA were randomized to receive either placebo or tramadol (3 mg/kg PO every 12 h) for 19 days, 
 
295 with a crossover following a 3-month washout period (Monteiro et al., 2017). Outcome measures 
 
296 again included PVF, MA, and RMTS, though the PVF data set was incomplete due to technical 
 
297 problems. The group found that both PVF and RMTS were able to discriminate between normal 
 
298 and affected cats at baseline. They also found significant within and between-group increases in 
 
299 all outcome measures in OA-affected cats after treatment with tramadol (Monteiro et al., 2017). 
 
300 Mydriasis, sedation, hypersalivation, vomiting, and stomatorrhagia were observed in cats 
 
301 receiving tramadol (Monteiro et al., 2016; Monteiro et al., 2017). It is suspected that the reported 
 
302 bitter taste of the medication is responsible for the latter observations. 
 
303 
 
304 While additional research in a larger cohort of client-owned cats would be ideal, the 
 
305 pharmacokinetic data, and recent work suggesting that tramadol may help with maladaptive 
 
306 components of chronic pain is encouraging. Aversion to administration of medication may 
 
307 present a problem with clinical use, and may require compounding or reformulation. 
 
308 
 
309 Amantadine 
 
310 Amantadine is used both as an antiviral medication (via unknown mechanism) in human 
 
311 medicine, as well as for treatment of Parkinson’s, due to its modulatory effects on CNS 
 
312 dopamine concentrations (Hubsher et al., 2012). Amantadine has also been described as an N- 
313 methyl-D- aspartate (NMDA) antagonist (Blanpied et al., 2005), resulting in its evaluation as an 
 
314 analgesic (Bujak-Giżycka et al., 2012). The NMDA receptor, and its ligand, glutamate, have long 
 
315 been implicated in the development and maintenance of central plasticity, via increased and 
 
316 sustained excitation of neurons and subsequent alterations of gene and receptor expression 
 
317 (Latremoliere and Woolf, 2009; Baron et al., 2013). Blockade of these receptors with NMDA 
 
318 antagonists has been shown to both prevent the development of central plasticity, as well as treat 
 
319 the condition in affected animals (Wang et al., 2015; Tabakoff et al., 2016). 
 
320 
 
321 Amantadine’s use in cats stems from anecdotal reports of efficacy (Robertson, 2008a), or 
 
322 from demonstrated efficacy in dogs when used in conjunction with the NSAID meloxicam 
 
323 (Lascelles et al., 2008). In this latter study, amantadine was evaluated in dogs with OA that were 
 
324 not fully responsive to NSAID therapy (maladaptive pain was suspected, though not specifically 
 
325 assessed for), and found to be beneficial (Lascelles et al., 2008). While not indicative of 
 
326 amantadine’s efficacy as a sole analgesic, these data suggested promise when used as a part of 
 
327 multi-drug therapy, or in NSAID refractory cases. 
 
328 
 
329 The pharmacokinetics of amantadine in six healthy adult female spayed cats has been 
 
330 described (Siao et al., 2011b). Treatment groups included either 5 mg/kg administered orally or 
 
331 an IV infusion of 0.5 mg/kg*min for 10 min. Oral absorption of the drug was complete. The 
 
332 terminal half-life was calculated as 5.8 h and 5.4 h for IV and oral administration, respectively. 
 
333 Time to maximal concentration (Tmax) after oral administration ranged between 1.5 and 5 h, with 
 
334 a CMAX of 1.1 ± 0.1 µg/mL. Subsequent research aimed to evaluate amantadine’s effect on 
 
335 oxymorphone-induced thermal antinociception (Siao et al., 2011a). A constant rate infusion 
336 (CRI) targeting the 1100 ng/mL Cmax or an equivalent volume of saline were administered in 
 
337 combination with increasing oxymorphone CRI concentrations ranging from 0 to 0.4 µg/mL, 
 
338 chosen to approximate clinically relevant doses/concentrations (Siao et al., 2011a). Overall, there 
 
339 was no effect of amantadine on thermal thresholds, however, similar to gabapentin, amantadine 
 
340 may require changes present in the maladaptive pain state to exert appreciable effects. As no data 
 
341 exist for minimum effective concentrations, no dosing recommendations were made. The current 
 
342 recommendation is 3-5 mg/kg PO once daily according to other sources, likely derived from the 
 
343 work in dogs. 
 
344 
 
345 Amantadine’s mechanism of action makes it an attractive candidate for further evaluation 
 
346 in cats. However, clinical data showing efficacy of amantadine is currently lacking. 
 
347 
 
348 Amitriptyline 
 
349 Amitriptyline is a tricyclic antidepressant (TCA) that exerts its effect by inhibiting 
 
350 reuptake of the neurotransmitters serotonin, norepinephrine, and to a lesser effect, dopamine 
 
351 (Moore et al., 2012). It has also been shown to inhibit H1 release from mast cells in vitro (Gurgel 
 
352 et al., 2013). While its use in veterinary medicine has been limited primarily to behavioral 
 
353 disorders (Chew et al., 1998; Virga et al., 2001; Overall and Dunham, 2002), research in humans 
 
354 has demonstrated an analgesic effect in those suffering from interstitial cystitis (a urinary bladder 
 
355 disease with a chronic, neurogenic pain component; Hanno et al., 1989), and the drug is 
 
356 commonly used to treat neuropathic pain (Moore et al., 2012). 
 
357 
358 Due to the similarity of interstitial cystitis in humans, and idiopathic cystitis (IC) in cats, 
 
359 both proposed to have a neurogenic or neuropathic pain component, amitriptyline has been 
 
360 evaluated for efficacy in IC (Chew et al., 1998). Fifteen client-owned cats with severe, recurrent 
 
361 IC received 10 mg PO once daily, for up to 12 months in a non-blinded study. The number of 
 
362 cats reported to be free of clinical signs of disease at 6 and 12 months were 11 and nine, 
 
363 respectively. No changes in the cystoscopic examinations were apparent. It is thought that the 
 
364 clinical improvement, combined with the lack of changes in cystoscopy findings, indicates that 
 
365 amitriptyline’s efficacy is limited to treatment of the pain and discomfort associated with the 
 
366 disorder (Chew et al., 1998). However, urinary retention secondary to amitriptyline’s anti- 
 
367 cholinergic effect is another possibility. While placebo-controlled studies have evaluated 
 
368 amitriptyline’s efficacy for the treatment of feline lower urinary tract disease (an umbrella term 
 
369 which includes IC), no benefit against placebo was appreciated (Kraijer et al., 2003; Kruger et 
 
370 al., 2003). However, these studies evaluated resolution of clinical signs of urinary disease after 
 
371 short term administration of the drug, so placebo-controlled data evaluating clinical signs of pain 
 
372 after long-term administration is still necessary. 
 
373 
 
374 The effect of amitriptyline on segmental inhibition, a physiological process that reduces 
 
375 the transmission of pain signals, was evaluated in 21 adult anesthetized cats (Fromm et al., 
 
376 1991). The genders and breeds of the cats are not reported. The segmental inhibition of wide 
 
377 dynamic range neurons, which populate the dorsal horn and respond to all somatosensory inputs, 
 
378 was significantly increased by IV doses of 1.0 – 4.0 mg/kg of the drug, though no effect was 
 
379 seen on responsiveness to low-threshold mechanoreceptors. This may be beneficial with 
380 maladaptive pain, where amitriptyline may be able to help correct the dysfunctional inhibitory 
 
381 processes of the CNS that have been demonstrated in models of maladaptive pain. 
 
382 
 
383 There are currently no data on the pharmacokinetics of amitriptyline in the cat, which 
 
384 would be important for making dosing recommendations. The drug’s reported bitter taste, and 
 
385 potential side effects such as reduced grooming, sedation, and weight gain may limit its 
 
386 utilization (Chew et al., 1998). Validated, and if possible, objective measures should be used to 
 
387 establish efficacy for other chronic or maladaptive pain conditions in the cat before making 
 
388 treatment recommendations. 
 
389 
 
390 Flupirtine 
 
391 Flupirtine is an aminopyridine drug, which is classified as a selective neuronal potassium 
 
392 channel opener (SNEPCO; Devulder, 2010; De Vito et al., 2014). The mechanism of action is 
 
393 via interaction with G-protein-regulated, inwardly rectifying K+ channels (GIRKs), a class of 
 
394 potassium channels separate from the voltage-gated family. Activation of GIRKs by flupirtine 
 
395 results in stabilization of the membrane potential by generation of a hyperpolarizing current, and 
 
396 thus, decreased neuronal excitability. Flupirtine also indirectly inhibits the NMDA receptor due 
 
397 to its role as an oxidizing agent at the receptor’s redox site, which maintains the magnesium 
 
398 block on the NMDA receptor (Devulder, 2010; De Vito et al., 2014). 
 
399 
 
400 Flupirtine has historical use in Europe for a range of painful conditions in humans, 
 
401 including chronic pain, migraines, musculoskeletal back pain, myofascial pain, and for 
 
402 postoperative pain (Devulder, 2010; Harish et al., 2012). Opioid-sparing effects have also been 
403 demonstrated. Unfortunately, acute hepatotoxicity (some cases requiring liver transplants) has 
 
404 been reported in humans (Douros et al., 2013). 
 
405 
 
406 Six healthy mixed breed adult cats (three male, three female) received single doses of 
 
407 flupirtine at 5 mg/kg IV and PO in one study (De Vito et al., 2014). The calculated 
 
408 bioavailability was 39.3  9.7%, with a TMAX of 2.78 h  0.77 after oral administration of the 
 
409 drug. The elimination half-life was reported as 13.67  4.43 h after oral dosing, compared to an 
 
410 intravenous elimination half-life of 11.31  2.24 h. 
 
411 
 
412 Some data exist for efficacy of the drug in an electrical tooth pulp model in dogs and cats, 
 
413 which revealed an ED50 of 3.5 mg/kg PO for dogs, and 3.0 mg/kg for cats (Gordon et al., 1987; 
 
414 Nickel, 1987). Unfortunately, the remaining evidence of efficacy is limited to non-companion 
 
415 animal models, including efficacy in different models of pain in rodents (Kolosov et al., 2012). 
 
416 
 
417 Flupirtine’s novel mechanism of action makes it an attractive candidate for evaluation, 
 
418 though the drug’s current availability in only European and Asian countries is a limitation. 
 
419 
 
420 Tapentadol 
 
421 Tapentadol is part of a new class of drugs known as MORphine receptor agonist- 
 
422 Noradrenaline Reuptake Inhibitors (MOR-NRI), and shares structural similarities with tramadol 
 
423 (Pergolizzi et al., 2012; Taylor et al., 2013). Tapentadol’s MOR affinity is 50-fold less than that 
 
424 of morphine, which appears to translate to a decrease in the typical opioid associated adverse 
 
425 effects such as pruritus, vomiting, decreased GI motility, and diarrhea (Pergolizzi et al., 2012). It 
426 also only exists as a single enantiomer, and only the parent compound exerts the MOR-NRI 
 
427 effects, in contrast with tramadol. Some aspects of the drug, including its weak antimuscarinic 
 
428 effect, poor oral bioavailability, and weak 5-HT3 antagonism may impair its utility (Giorgi et al., 
 
429 2012). 
 
430 
 
431 Tapentadol’s disposition after IV, IM, and SC administration (5 mg/kg) in six healthy 
 
432 adult mixed-breed cats has been characterized (Lee et al., 2013). Bioavailability was high, at 
 
433 93.93  9.91% and 90.01  6.52% for IM and SQ administration, respectively. Terminal half-life 
 
434 was calculated to be 2.93  0.86 h, 2.28  0.85 h, and 2.05  0.6 h for IV, IM and SQ 
 
435 respectively. Side effects were similar to those previously reported in dogs (salivation, panting, 
 
436 etc.), though agitation was also seen in some cats, as is typical with opioids. There are some data 
 
437 evaluating the efficacy of orally administered tapentadol on thermal antinociception in cats 
 
438 (Doodnaught et al., 2017). Six healthy adult cats (4 females, 2 males) received either placebo, IM 
 
439 buprenorphine (0.02 mg/kg) or tapentadol (25 mg or 50 mg) orally in a randomized crossover 
 
440 study. Tapentadol was found to have a significant effect on skin thermal thresholds at 1 and 1-2 h 
 
441 (25mg and 50mg, respectively) when compared to baseline, but not when compared to placebo. 
 
442 This is contrasted to buprenorphine’s efficacy at 1 and 2 h when compared against placebo. No 
 
443 pharmacokinetic data was collected or reported. 
 
444 
 
445 Currently, only parenteral routes of administration have been evaluated, with no data on 
 
446 potential efficacy in the cat. These data (oral pharmacokinetics and analgesic efficacy in the cat) 
 
447 are needed before any treatment recommendations can be made. 
 
448 
449 Maropitant 
 
450 
 
451 Maropitant is a potent and selective neurokinin-1 receptor (NK-1R) antagonist that 
 
452 functions as a central and peripheral anti-emetic (Hickman et al., 2008). This receptor is also 
 
453 shared by the ligand Substance P (SP), which has been studied for its role in inflammatory and 
 
454 nociceptive pathways (O'Connor et al., 2004). It is likely the knowledge that maropitant may 
 
455 have NK-1 antagonist activity, the known role of SP/NK-1 in pain and FDA approval for 
 
456 maropitant (Cerenia) in veterinary species has led to interest in evaluating the drug for 
 
457 analgesic effects. 
 
458 
 
459 The pharmacokinetics of maropitant administered both intravenously and orally (1 
 
460 mg/kg) and of the drug administered subcutaneously (1 mg/kg) was evaluated in four mixed 
 
461 breed cats (Hickman et al., 2008). Oral bioavailability of the drug was low at 50%, while 
 
462 subcutaneous administration resulted complete absorption. Across the different routes of 
 
463 administration, the half life varied: 16.5, 13.1, and 17.1 h for IV, oral, and subcutaneous 
 
464 administration respectively. TMAX values ranged from 2-3 h for oral administration, and 0.5 -2 h 
 
465 after subcutaneous administration, with corresponding CMAX values of 156 ng/mL and 269 
 
466 ng/mL respectively. Variability for these reported values were quite high, likely due in part to the 
 
467 small sample size. 
 
468 
 
469 The anesthetic-sparing effects of intravenous maropitant (1 and 5 mg/kg) was evaluated 
 
470 in 10 female cats using an ovarian stimulation model previously developed in the dog (Niyom et 
 
471 al., 2013). The study found a significant MAC reduction effect of both the 1 mg/kg and 5mg/kg 
472 doses of maropitant, but they were not different from each other. However, it is important to note 
 
473 that MAC reduction cannot be assumed to translate into analgesia, as demonstrated by 
 
474 midazolam (Seddighi et al., 2011). 
 
475 
 
476 While initial pharmacological data are available, there is currently insufficient data for 
 
477 pain therapeutic recommendations to be made due to lack of efficacy data. Additionally, it is 
 
478 important to note NK-1 receptor antagonists have failed clinical trials for multiple painful 
 
479 conditions in humans (Hill, 2000). Possible causes for this include parallel pathways in the 
 
480 transmission of pain which reduce the importance of any one ligand or receptor, as well as a 
 
481 misinterpretation of anxiolysis as analgesia in pre-clinical animal data (Hill, 2000). 
 
482 
 
483 
 
484 Future medications in development 
 
485 Grapiprant 
 
486 Grapiprant is a selective prostaglandin E receptor 4 (EP4) antagonist that is part of a new 
 
487 class of drugs, the piprants, which work by blocking prostaglandin E2 (PGE2) receptors (De Vito 
 
488 et al., 2016). Research has indicated that the EP4 receptor is important in mediating pain 
 
489 associated with both rheumatoid and osteoarthritis, as well as inflammation in general (St- 
 
490 Jacques and Ma, 2013). However, this mechanism of action can be considered similar to 
 
491 traditional NSAIDs, and so grapiprant may not be efficacious for pain syndromes with a 
 
492 primarily maladaptive drive. 
 
493 
494 While pharmacokinetic and clinical data of efficacy is available for dogs with 
 
495 osteoarthritis, only safety and toxicokinetic data are available in cats (Rausch-Derra et al., 2016; 
 
496 Rausch-Derra and Rhodes, 2016; Łebkowska-Wieruszewska et al., 2017). Grapiprant was 
 
497 administered to 24 healthy cats at doses ranging from 0 mg/kg to 15 mg/kg PO once daily for a 
 
498 28-day period, with pharmacokinetic sampling occurring on Days 0 and 27. The half-life was 
 
499 quite variable, ranging from 2.08  0.51 h in the 3 mg/kg male cat group on Day 0, to 14.12 h in 
 
500 the 3 mg/kg female cat group on Day 27. The reason for this wide disparity is unknown, but 
 
501 potentially related to the formulation (gel capsules) and prolonged residence in the GI tract of 
 
502 some cats. Significant accumulation was not seen, and there did not appear to be a relation 
 
503 between dosage and exposure. Minor clinical pathological abnormalities were reported, 
 
504 including changes in clotting times and hemoglobin, but not considered clinically relevant. Most 
 
505 importantly however, no GI or renal abnormalities were observed, in contrast to the concerns 
 
506 associated with the use of COX-inhibiting NSAIDs in cats. While the drug is still in early stages 
 
507 of evaluation in the cat, its potential as an anti-inflammatory, analgesic drug with an apparently 
 
508 good safety profile is encouraging.  In the future, it is hoped that more robust pharmacokinetic 
 
509 and pharmacodynamic data become available, particularly studies of clinical efficacy in chronic 
 
510 pain conditions. 
 
511 
 
512 Anti-nerve growth factor antibodies 
 
513 There has been a recent interest in inhibiting Nerve Growth Factor (NGF), a protein that 
 
514 regulates the growth, maintenance, and survival of neurons in the developing animal (Hefti et al., 
 
515 2006; Chang et al., 2016). It is known that NGF levels are increased within the joints of humans 
 
516 and dogs affected by osteoarthritis (Halliday et al., 1998; Isola et al., 2011), where it can act to 
517 increase sensitivity and excitability of nociceptors, in addition to stimulating the growth of new 
 
518 nerve fibers into inflamed tissue (Hefti et al., 2006; Chang et al., 2016). NGF has its actions via 
 
519 binding to a specific tyrosine kinase receptor (TrkA; Hefti et al., 2006). The resulting signaling 
 
520 cascade eventually produces changes in the transient receptor potential vanilloid receptor 1 
 
521 (TRPV1) cation channel, which increases both the TRPV1 channel’s excitability, as well as the 
 
522 production of other pro-excitation proteins (Hefti et al., 2006). NGF is also known to activate 
 
523 mast cells, whose cellular products can increase sensitization of neurons (Chang et al., 2016). 
 
524 
 
525 Both dog-specific and cat-specific (ranevetmab and frunevetmab, respectively) 
 
526 monoclonal antibodies against NGF have been developed, evaluated in pilot trials (Lascelles et 
 
527 al., 2015; Gruen et al., 2016), and demonstrated efficacy. Cats were required to have both 
 
528 chronic musculoskeletal disease and pain, based on physical, orthopedic, and radiographic 
 
529 examination, as well as owner-assessed pain or mobility impairment. Cats received a single 
 
530 injection of either 0.4 mg/kg or 0.8 mg/kg SC and demonstrated significant improvement 
 
531 compared to placebo in both objective measures of activity (accelerometer data) and subjective 
 
532 measures (veterinarian and owner assessments). In cats, the beneficial effect on activity was 
 
533 observed for 6 weeks. This is the first study that demonstrated an owner-assessed significant 
 
534 positive effect compared to placebo for chronic pain in cats. No adverse effects were reported. 
 
535 Currently, the role of anti-NGF antibody in treating central processes is unclear – we know that 
 
536 the biologic acts peripherally, but the robust efficacy suggests that there may be some 
 
537 modulation of central processes as well. 
 
538 
539 Pharmacokinetic data for NV-02 (the felinized antibody) is available for doses ranging 
 
540 from 2 mg/kg to 28 mg/kg SQ in 8 healthy cats (Gearing et al., 2016). TMAX had a reported range 
 
541 of 1.9-4.3 days, and the half-life ranged from 7 to 15 days. 
 
542 
 
543 The data available for the felinizied anti-NGF antibody, including a long duration of 
 
544 action with few adverse effects, is promising. This biologic would be beneficial for cats in which 
 
545 oral administration of medications is not possible, or in cats where NSAIDs are not indicated. 
 
546 More pharmacologic and efficacy data are needed. 
 
547 
 
548 On a related note, development of anti-TNFα biologics have been reported, which may 
 
549 also be efficacious in maladaptive pain states, given the role of TNFα in maladaptive pain 
 
550 (Nexvet, 2016). However, insufficient information for discussion is available at this time. 
 
551 
 
552 Conclusions 
 
553 Much is known about the neurobiology of chronic and maladaptive pain in rodent 
 
554 models, but conditions associated with maladaptive pain in cats have been recognized. Despite 
 
555 the interest in maladaptive pain in cats, assessing and measuring the pain still remains 
 
556 challenging and this hinders the assessment of putative analgesics. Treatment of chronic pain 
 
557 states in the cat thus remains a challenge, as only NSAIDs have extensively been clinically 
 
558 evaluated for long-term analgesia efficacy and safety. However, there are several drugs with 
 
559 mechanisms of action that make them attractive for the treatment of maladaptive pain, including 
 
560 gabapentin, tramadol, amantadine and others. More data on the pharmacokinetics and 
 
561 pharmacodynamics of these drugs in cats is needed to guide treatment. 
562 
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893 Table 1  
894 Drugs featured in this review and their mechanisms of action 
 
Drug Mechanism 
a
 
 NSAIDs COX 1 and/or COX 2 antagonism 
 Gabapentin α2δ-1 subunit of voltage-gated calcium channels 
 Tramadol µ-opioid receptor agonism, norepinephrine and serotonin reuptake inhibition, α-2 
  adrenergic receptor antagonism 
 Amantadine NMDA antagonism 
 Amitriptyline 
Flupirtine 
Serotonin, norepinephrine, dopamine reuptake inhibition 
G-protein-regulated, inwardly rectifying K
+ 
channel agonism, NMDA 
  antagonism 
 Tapentadol µ-opioid receptor agonism, norepinephrine reuptake inhibition 
 Maropitant Neurokinin 1 receptor antagonism 
 Grapiprant Prostaglandin E4 receptor antagonism 
 Frunevetmab Antibody against nerve growth factor 
895 COX, cyclo-oxygenase; NMDA, N-methyl-D-aspartate 
896 a  Generally accepted mechanism of action. There may be differences in the cat for some of the 
897 drugs dependent on metabolism 
898 
899 Figure legends 
 
900 
 
901 Fig. 1. Schematic illustration of Adaptive Pain. Nociceptive Pain - A noxious stimulus (red 
 
902 starburst) activates high-threshold nociceptive primary afferent sensory neurons (red/yellow line) 
 
903 with cell bodies in the dorsal root ganglion (DRG), and termination in the dorsal horn (DH). 
 
904 Here, the afferent signal is transmitted to the second order neuron via mono- or multi-synaptic 
 
905 processes, and crosses over to the other side of the spinal cord, then transmitted to the brain via 
 
906 ascending tracts in the spinal cord (red arrow), where it is interpreted as a warning of actual or 
 
907 potential tissue damage. There is tonically active descending inhibition (green line) from the 
 
908 CNS (channeled via the rostro-ventromedulla) that helps control whether the information from 
 
909 the primary afferent neuron is blocked at the level of entry into the DH of the spinal cord. 
 
910 Inflammatory Pain - Local tissue damage results in release of inflammatory mediators, 
 
911 recruitment of inflammatory cells and further release of inflammatory mediators. These 
 
912 mediators either sensitize sensory nerves, or directly stimulate them, resulting in a lowering of 
 
913 thresholds in sensory nerves and generation of action potentials (nociceptive signals). These 
 
914 signals are carried by afferent neurons (red line) with cell bodies in the DRG and terminals in the 
 
915 DH. As before, ascending fibers carry the nociceptive input to the brain along ascending tracts 
 
916 (red arrow), and descending inhibitory signals (green line) may dampen down the input at the 
 
917 level of the spinal cord. The increased sensitivity in the periphery associated with inflammatory 
 
918 pain following tissue damage promotes protection of the area, allowing it to heal. 
 
919 
 
920 Fig. 2. Schematic illustration of Maladaptive Pain. Neuropathic Pain – Physical damage to 
 
921 nervous system tissue (e.g. in this case, a tumor - yellow circle) results in very abnormal 
922 activation of nociceptor sensory neurons – they become activated in response to previously sub- 
 
923 threshold stimuli (blue circle). The subsequent pathway is as described in ‘Adaptive’ pain, but at 
 
924 the level of the dorsal root ganglion (DRG) and the dorsal horn of the spinal cord there are 
 
925 changes (nervous system plasticity) resulting in amplification of the signals and facilitation of 
 
926 throughput of the signals. Additionally, the tonically active descending inhibition is less effective 
 
927 (illustrated as a dashed green line), which again facilitates the signals being transmitted from the 
 
928 periphery to higher centers. Hypersensitivity (increased pain from a stimulus that normally 
 
929 provokes pain) and allodynia (pain due to a stimulus that does not normally provoke pain) occur 
 
930 as a result of these changes, and in addition, spontaneous pain can occur due to abnormal activity 
 
931 in the nervous system (e.g. generated at the site of nervous system injury). 
 
932 A hallmark of ‘neuropathic pain’ is the presence of actual physical damage to part of the nervous 
 
933 system and it is this that drives the changes in the way the system functions. Functional pain – In 
 
934 Functional Maladaptive pain, the nervous system is grossly normal – there is no physical damage 
 
935 of the system. However, the functioning of the system is abnormal. This abnormal central 
 
936 processing results from repeated input to the system, causing nervous system plasticity (changes 
 
937 in neurons and changes in the way supporting elements [e.g. microglia] communicate with 
 
938 neurons) and thus amplification and facilitation of the processing of nociceptive information. 
 
939 Under these conditions, a previously sub-threshold stimulus (blue circle) activates a physically 
 
940 normal nociceptor (red line) but abnormal central processing in the spinal cord or brain (inset) 
 
941 results in the stimulus being interpreted as painful. As with neuropathic pain, descending 
 
942 inhibition may be defective (dashed green line). 
943 Hypersensitivity (increased pain from a stimulus that normally provokes pain) and allodynia 
 
944 (pain due to a stimulus that does not normally provoke pain) occur as a result of these changes, 
 
945 and in addition, spontaneous pain can occur due to abnormal activity in the nervous system. 
 
946 
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*Highlights (for review) - Chronic Maladaptive pain in Cats 
 
 
 
 
1 Highlights 
2 
3 Chronic Maladaptive Pain in Cats: A Review of Current and Future Drug Treatment Options 
4 
5 • Maladaptive pain can involve actual damage to neural tissue and/or changes in nociceptive 
6 processing. 
7 • Techniques like activity data, owner questionnaires, QST, and NWR may help in identifying 
8 maladaptive pain in the cat. 
9 • Options for long-term pain control in the cat are lacking, with no drugs approved in North 
10 America, and one worldwide. 
11 • While some data are available for potential therapies, most is limited to normal cats with poor 
12 measurements of efficacy. 
13 • It is hoped that future research will yield a better understanding of maladaptive pain the cat and 
14 potential treatments. 
